Indolent Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Indolent Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Studying TAK-243 in Patients With Advanced Cancer [Phase 1]
This entry describes a Phase 1 clinical trial evaluating TAK-243 in adults with advanced cancers, including non-Hodgkin lymphoma and various…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy [Phase 2]
Phase 2 clinical trial evaluating a CD3xCD20 bispecific antibody for relapse/refractory B-cell non-Hodgkin lymphomas after CAR-T therapy has…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating glofitamab and obinutuzumab in indolent non-Hodgkin lymphomas, including follicular lymphoma and marginal …
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating pomalidomide in combination with obinutuzumab for relapsed/refractory indolent non-Hodgkin lymphoma; the…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma [Phase 1]
An early-phase study evaluating the combination of parsaclisib with standard therapy in newly diagnosed, high-risk diffuse large B-cell lymp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating ultra-low-dose orbital radiation therapy for Stage I-IV indolent B-cell non-Hodgkin lymphoma and mantle cell lympho…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 clinical trial of Axicabtagene Ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (follicular and marginal zone lymphom…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study of lenalidomide plus rituximab in previously untreated indolent non-Hodgkin lymphoma was terminated; results have been poste…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]
This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memoria…
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Indolent Non Follicular Lymphomas Prognostic Project
The clinical trial NCT02904577 focusing on prognostic factors for indolent non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on a Phase 1/2 study of lenalidomide in combination with obinutuzumab for relapsed indolent non-Hodgkin lymphoma, incl…
-
CLINICAL_TRIALS trial_result · 2025-06-09Clinical Trial Update: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL [Phase 1, Phase 2]
Phase 1/2 study of ATG-010 with lenalidomide and rituximab in adults with diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study of blinatumomab in relapsed or refractory indolent non-Hodgkin lymphoma has been terminated. Results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL [Phase 1, Phase 2]
Clinical trial update for a Phase 1/2 study of linperlisib in combination with rituximab in relapsed/refractory indolent non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
This Phase 2 trial investigates reduced-intensity chemotherapy and radiation therapy before donor stem cell transplantation for various hema…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) [Phase 3]
A Phase 3 trial evaluated copanlisib in combination with standard immunochemotherapy for relapsed indolent non-Hodgkin lymphoma. The study w…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
This clinical trial update describes real-world patterns of copanlisib use in people with relapsed or refractory Indolent Non-Hodgkin Lympho…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma [Phase 2]
This Phase 2 study comparing two intermittent dosing schedules of duvelisib in indolent non-Hodgkin lymphoma has completed, with results pos…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Phase III Copanlisib in Rituximab-refractory iNHL [Phase 3]
Phase III trial update for copanlisib in rituximab-refractory indolent non-Hodgkin lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. [Phase 2]
Phase 2 trial update examining IBI376 plus rituximab in untreated indolent lymphoma (non-Hodgkin lymphoma).
-
CLINICAL_TRIALS trial_result · 2023-04-14Clinical Trial Update: A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma [Phase 3]
Phase 3 trial evaluating ibrutinib in combination with either bendamustine/rituximab or rituximab-based regimen in previously treated indole…
-
CLINICAL_TRIALS trial_result · 2023-03-31Clinical Trial Update: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years [Phase 2]
Phase 2 trial update on first-line therapy for advanced Follicular Lymphoma in patients under 60 not eligible for standard immunochemotherap…
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) [Phase 3]
Phase 3 trial evaluating Copanlisib in combination with Rituximab in relapsed indolent B-cell non-Hodgkin lymphoma has completed with result…
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide in combination with rituximab for various stage III/IV indolent non-Hodgkin lymphoma subtypes; study c…